Syngene International Ltd. (SYNGENE) fundamentals
Syngene International Ltd. is a listed company in Healthcare Services, part of the Healthcare sector, listed on the NSE as SYNGENE (ISIN INE398R01022). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Syngene International Ltd. does
Syngene International Limited is an India-based integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The Company's services include discovery, development, manufacturing, SynVent Integrated Drug discovery, dedicated centers, and Center for Advanced Protein Studies (CAPS). Its discovery services span the entire spectrum of early-stage research from target identification to delivery of drug candidates for further development. It offers preclinical development, active pharmaceutical ingredient and drug product development for both small molecules and biologics. It has capabilities for current Good Manufacturing Practices (cGMP) manufacturing from benchtop volume to commercial scale. SynVent is its drug discovery platform for enabling fully integrated therapeutic drug discovery and development across small molecules, new modalities and biologics.
Valuation and market data
| Last close | ₹359.85 |
|---|---|
| Market capitalisation | ₹14,481 crore |
| Enterprise value | ₹14,916 crore |
| P/E (TTM) | 45.72 |
| Price to book | 2.99 |
| Price to sales (TTM) | 2.28 |
| Book value per share | ₹120.25 |
| Dividend yield | 34.74% |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Listed since | Tue Aug 11 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹3,809 crore | ₹411 crore | ₹317 crore | 7.87 |
| Mar 2025 | ₹3,714 crore | ₹660 crore | ₹496 crore | 12.35 |
| Mar 2024 | ₹3,579 crore | ₹621 crore | ₹510 crore | 12.71 |
| Mar 2023 | ₹3,264 crore | ₹594 crore | ₹464 crore | 11.59 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 52.6% |
|---|---|
| Foreign institutions (FII) | 10.1% |
| Mutual funds | 27.1% |
| Other domestic institutions | 2.2% |
| Retail and others | 8.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.